Evidence map›Paper›PMID 31515708›Full record

ArticleInternational journal of hematology2020

Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Machiko Fujioka, Hidehiro Itonaga, Takeharu Kato, Yasuhito Nannya, Miki Hashimoto, Sachie Kasai, Eo Toriyama, Rena Kamijo, Masataka Taguchi, Hiroaki Taniguchi and 7 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Machiko FujiokaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Hidehiro ItonagaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan. itonaga-ngs@umin.ac.jp.ORCID http://orcid.org/0000-0003-1438-3623
Takeharu KatoDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Miki HashimotoDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.
Sachie KasaiDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Eo ToriyamaDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Rena KamijoDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Masataka TaguchiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Hiroaki TaniguchiDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Sunao AtogamiDepartment of Laboratory Medicine, Sasebo City General Hospital, Sasebo, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.
Tomoko HataDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Sasebo City General Hospital · JPNagasaki University · JPNagasaki University Hospital · JPKyoto University · JPNagasaki Medical Center · JP

Funding

Japan Society for the Promotion of Science #17K16189
6 · The paper itself

Abstract

A 68-year-old male was diagnosed with acute promyelocytic leukemia (APL). A G-banding chromosomal analysis revealed the co-existence of two clones: one with del(20q) and t(15;17)(q22;q12) and another with del(20q) alone. During the remission of APL following treatment with all-trans-retinoic acid, del(20q) was persistently identified, indicating a diagnosis of cytogenetic abnormalities of undetermined significance (CCAUS) with isolated del(20q). Bicytopenia developed 48 months after the remission of APL. The presence of isolated del(20q) was detected in the G-banding analysis, whereas morphological dysplasia of hematopoietic cells was not confirmed. This case showed indolent progression from CCAUS after the remission of APL to clonal cytopenia of undetermined significance (CCUS). CCUS with isolated del(20q) persisted for 24 months without any finding of hematological malignancies. At the most recent follow-up, targeted capture sequencing showed the U2AF1 S34F mutation. Considerable attention needs to be paid in follow-ups for CCAUS with del(20q) after the treatment of leukemia.

Indexed as

Chromosome AberrationsAgedClone CellsFollow-Up StudiesHumansLeukemia, Promyelocytic, AcuteMaleRemission InductionTretinoinTretinoinAcute promyelocytic leukemiaAll-trans-retinoic acidClonal hematopoiesisCytopenia of undetermined significance (CCUS)del(20q)

Identifiers

PMID31515708
OpenAlexW2972308026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.